| 【Company Research】Botanee Biotech (300957 CH) – ESOP targets stabilize earnings expectation but sentiment overhang remains |
| 【Company Research】GAC Group (2238 HK) – Impairment as always; eyes on Aion’s upmarket |
| CMBI Fixed Income: Hopson: weaker but much better than peers FY22 results |
| 【Company Research】RemeGen (9995 HK) – Wide clinical studies to unlock global potential |
| 【Company Research】Tigermed (300347 CH) – Targeting the broad global market |
| 【Company Research】Zoomlion (000157 CH) – Surprise on dividend; Potential resumption of A-share repurchase; U/G to BUY |
| 【Company Research】Zoomlion (1157 HK) – Surprise on dividend; Recovery in sight |
| 【Company Research】Dingdang Health (9886 HK) – Long-term growth outlook remains intact |
| 【Company Research】Innovent Biologics (1801 HK) – Revenue growth to recover in 2023 |
| 【Company Research】BYDE (285 HK) – FY22 largely in-line; Gradual recovery on track |
公司地址：香港中环花园道三号冠君大厦45-46楼
电话：（852）3900-0888 传真：（852）3761-8788
招银国际版权所有 Copyright © 2019-2026 CMB International Capital Corporation Limited. All rights reserved.
